RCUS
Arcus Biosciences, Inc.
$23.80
+2.15%
$3.0B
No data for this timeframe.
Vol
Market Cap$3.0B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (78%)
Inst. Holders50 funds
Inst. Value$1.3B
Inst. Activity10 buys / 8 sells
Insider Activity0B / 2S
Insider Net $-$265.0K
SEC Reports4
Recent Activity
Jun 12, 2026
short_volume
Short Volume: RCUS — 63.2% short (0.3M / 0.5M)
Short: 344,544 | Exempt: 124 | TRF Vol: 544,987 | Short Ratio: 63.2% | Off-exchange volume (dark poo
Jun 11, 2026
Insider
Lambert Nicole was granted 16,900 shares
Director
Jun 11, 2026
Insider
KANEKO YASUNORI was granted 5,700 shares
Director
Jun 11, 2026
Insider
Tang Carolyn C. acquired via exercise 34,090 shares
General Counsel @ $2.57 ($87.7K)
Apr 21, 2026
SEC
Arcus Biosciences, Inc. is holding its 2026 Annual Meeting to vote on director elections, auditor appointment ratificati
DEFA14A — Impact 2/10
Apr 20, 2026
SEC
Arcus Biosciences announced the discontinuation of its Phase 3 STAR-121 trial in metastatic non-small cell lung cancer d
8-K — Impact 8/10
Apr 8, 2026
SEC
Jennifer Jarrett, an officer of Arcus Biosciences, filed a Form 144 to notify intent to sell 70,000 shares of common sto
144 — Impact 3/10
Inst.
Invesco Ltd. — ADD
820,820 shares ($17.7M)
Price Targets
$35.75
+50.2% upside
Strong Buy
Current $23.80
Low $22.00
Median $34.50
High $47.00
12 analysts
$22.00
$47.00
Analyst Ratings
5Strong Buy
9Buy
4Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 4, 2026 | LifeSci Capital | INITIATE | Outperform |
| May 11, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight → Equal-Weight |
| May 7, 2026 | Goldman Sachs | MAINTAIN | Buy → Buy |
| Apr 2, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| Mar 5, 2026 | Citigroup | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.81 ▼ -5.1% | $-1.04 — $-0.62 | 0% YoY | 7 |
| Next Q | $-0.83 ▼ -0.7% | $-1.07 — $-0.55 | 35% YoY | 7 |
| Current FY | $-3.48 | $-4.88 — $-2.63 | -6% YoY | 7 |
| Next FY | $-3.10 ▲ +2.0% | $-4.55 — $-1.55 | 11% YoY | 7 |
Latest Reports
NEUTRAL
DEFA14A
2/10
Arcus Biosciences, Inc. is holding its 2026 Annual Meeting to vote on director elections, auditor appointment ratificati
Apr 21, 2026
BEARISH
8-K
8/10
Arcus Biosciences announced the discontinuation of its Phase 3 STAR-121 trial in metastatic non-small cell lung cancer d
Apr 20, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $328.9M | ADD |
| WELLINGTON MANAGEMENT GROUP LLP | $131.5M | DOUBLED |
| STATE STREET CORP | $116.9M | ADD |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $92.3M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $83.3M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 11, 2026 | Lambert Nicole | A | $0.00 |
| Jun 11, 2026 | KANEKO YASUNORI | A | $0.00 |
| Jun 11, 2026 | Tang Carolyn | M | $87.7K |
| Jun 11, 2026 | FALBERG KATHRYN | A | $0.00 |
| Jun 11, 2026 | Lacey David | A | $0.00 |
50 institutional holders with $1.3B total value (58,281,606 shares) as of 2026-Q1. Top holders: BlackRock,, WELLINGTON, STATE. Net buying activity: 10 institutions added/increased vs 8 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 15,226,475 | $328.9M | 26.1% | ADD +27.0% |
| 2 | WELLINGTON MANAGEMENT GROUP LLP | 6,089,516 | $131.5M | 10.4% | DOUBLED +309.4% |
| 3 | STATE STREET CORP | 5,412,901 | $116.9M | 9.3% | ADD +34.8% |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4,272,056 | $92.3M | 7.3% | — |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 3,856,725 | $83.3M | 6.6% | — |
| 6 | Woodline Partners LP | 3,777,798 | $81.6M | 6.5% | — |
| 7 | MARSHALL WACE, LLP | 3,761,437 | $81.2M | 6.5% | NEW |
| 8 | BNP Paribas Asset Management Holding S.A. | 1,654,754 | $35.7M | 2.8% | — |
| 9 | DIMENSIONAL FUND ADVISORS LP | 1,426,223 | $30.8M | 2.4% | — |
| 10 | CITADEL ADVISORS LLC | 1,329,935 | $28.7M | 2.3% | — |
| 11 | FMR LLC | 1,165,252 | $25.2M | 2.0% | TRIM -50.6% |
| 12 | MORGAN STANLEY | 1,113,526 | $24.1M | 1.9% | — |
| 13 | GOLDMAN SACHS GROUP INC | 999,786 | $21.6M | 1.7% | — |
| 14 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 903,638 | $19.5M | 1.6% | — |
| 15 | Invesco Ltd. | 820,820 | $17.7M | 1.4% | ADD +98.1% |
| 16 | BANK OF AMERICA CORP /DE/ | 646,068 | $14.0M | 1.1% | TRIM -35.4% |
| 17 | VANGUARD FIDUCIARY TRUST CO | 582,920 | $12.6M | 1.0% | — |
| 18 | RENAISSANCE TECHNOLOGIES LLC | 424,700 | $9.2M | 0.7% | DOUBLED +1198.8% |
| 19 | BAKER BROS. ADVISORS LP | 415,621 | $9.0M | 0.7% | ADD +53.9% |
| 20 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 379,100 | $8.2M | 0.7% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Invesco Ltd. | ADD | 414,365 | 820,820 | +98.1% | $17.7M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,000,818 | 646,068 | -35.4% | $14.0M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 32,700 | 424,700 | +1198.8% | $9.2M | 2026-Q1 |
| BAKER BROS. ADVISORS LP | ADD | 270,000 | 415,621 | +53.9% | $9.0M | 2026-Q1 |
| Hudson Bay Capital Management LP | ADD | 240,000 | 356,535 | +48.6% | $7.7M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | ADD | 203,268 | 281,681 | +38.6% | $6.1M | 2026-Q1 |
| Nuveen, LLC | ADD | 141,600 | 221,710 | +56.6% | $4.8M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | TRIM | 225,913 | 160,082 | -29.1% | $3.5M | 2026-Q1 |
| Point72 Asset Management, L.P. | NEAR_EXIT | 3,280,000 | 129,273 | -96.1% | $2.8M | 2026-Q1 |
| Russell Investments Group, Ltd. | TRIM | 136,121 | 80,833 | -40.6% | $1.7M | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 1,511 | 20,171 | +1234.9% | $435.7K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | DOUBLED | 1,172 | 2,423 | +106.7% | $52.3K | 2026-Q1 |
| FEDERATED HERMES, INC. | NEAR_EXIT | 23,219 | 1,410 | -93.9% | $30.5K | 2026-Q1 |
| Allworth Financial LP | DOUBLED | 27 | 80 | +196.3% | $1.7K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 58,649 | 75,816 | +29.3% | $1.6K | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | EXIT | 815,561 | 0 | -100.0% | $0.00 | 2026-Q1 |
| FRANKLIN RESOURCES INC | EXIT | 853,491 | 0 | -100.0% | $0.00 | 2026-Q1 |
| TORONTO DOMINION BANK | EXIT | 1,484,699 | 0 | -100.0% | $0.00 | 2026-Q1 |
| BlackRock, Inc. | ADD | 11,810,866 | 14,997,891 | +27.0% | $357.4M | 2025-Q4 |
| WELLINGTON MANAGEMENT GROUP LLP | DOUBLED | 1,266,289 | 5,184,509 | +309.4% | $123.5M | 2025-Q4 |
| STATE STREET CORP | ADD | 3,394,854 | 4,576,969 | +34.8% | $109.1M | 2025-Q4 |
| MARSHALL WACE, LLP | NEW | — | 3,387,794 | — | $80.7M | 2025-Q4 |
| TORONTO DOMINION BANK | NEW | — | 1,484,699 | — | $35.4M | 2025-Q4 |
| FMR LLC | TRIM | 2,296,021 | 1,135,178 | -50.6% | $27.1M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,360,781 | 1,000,818 | -26.5% | $23.8M | 2025-Q4 |
10 unique insiders with 18 transactions. Net insider value: -$265.0K ($0.00 bought, $265.0K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | Lambert Nicole | Director | AWARD | 16,900 | — | — |
| Jun 11, 2026 | KANEKO YASUNORI | Director | AWARD | 5,700 | — | — |
| Jun 11, 2026 | Tang Carolyn C. | General Counsel | EXERCISE | 34,090 | $2.57 | $87.7K |
| Jun 11, 2026 | FALBERG KATHRYN E | Director | AWARD | 5,700 | — | — |
| Jun 11, 2026 | Lacey David L. | Director | AWARD | 16,900 | — | — |
| Jun 11, 2026 | Lambert Nicole | Director | AWARD | 5,700 | — | — |
| Jun 11, 2026 | Machado Patrick | Director | AWARD | 16,900 | — | — |
| Jun 11, 2026 | Ribas Antoni | Director | AWARD | 16,900 | — | — |
| Jun 11, 2026 | Machado Patrick | Director | AWARD | 5,700 | — | — |
| Jun 11, 2026 | KANEKO YASUNORI | Director | AWARD | 16,900 | — | — |
| Jun 11, 2026 | Lacey David L. | Director | AWARD | 5,700 | — | — |
| Jun 11, 2026 | Ribas Antoni | Director | AWARD | 5,700 | — | — |
| Jun 11, 2026 | FALBERG KATHRYN E | Director | AWARD | 16,900 | — | — |
| Jun 11, 2026 | PERLMAN ANDREW J | Director | AWARD | 5,700 | — | — |
| Jun 11, 2026 | PERLMAN ANDREW J | Director | AWARD | 16,900 | — | — |
| Jun 1, 2026 | Azoy Alexander | Chief Accounting Officer | SELL | 2,562 | $25.77 | $66.0K |
| May 11, 2026 | Goeltz II Robert C. | Chief Financial Officer | SELL | 7,763 | $25.63 | $199.0K |
| Dec 16, 2025 | Ribas Antoni | Director | GIFT | 5,050 | — | — |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 1 mixed, 2 neutral. Avg impact: 4.8/10.
NEUTRAL
DEFA14A
2/10
Arcus Biosciences, Inc. is holding its 2026 Annual Meeting to vote on director elections, auditor ap
Apr 21, 2026
BEARISH
8-K
8/10
Arcus Biosciences announced the discontinuation of its Phase 3 STAR-121 trial in metastatic non-smal
Apr 20, 2026
NEUTRAL
144
3/10
Jennifer Jarrett, an officer of Arcus Biosciences, filed a Form 144 to notify intent to sell 70,000
Apr 8, 2026
MIXED
8-K
6/10
Arcus Biosciences reported Q4 and full-year 2025 financial results, highlighting strong clinical dat
Feb 26, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (78% buy). Based on 18 analysts: 5 strong buy, 9 buy, 4 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$35.75 mean target
+50.2% upside
Strong Buy (1.46)
$22.00 Low
$47.00 High
| Metric | Value |
|---|---|
| Current Price | $23.80 |
| Target Low | $22.00 |
| Target Mean | $35.75 |
| Target Median | $34.50 |
| Target High | $47.00 |
| # Analysts | 12 |
| Recommendation | Strong Buy (1.46) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.81 | $-1.04 | $-0.62 | 0.0% | -5.1% | 1↑ 0↓ | $0.0B | -85.4% | 7 |
| Next Q 2026-09-30 |
$-0.83 | $-1.07 | $-0.55 | 35.0% | -0.7% | 3↑ 0↓ | $0.0B | -25.1% | 7 |
| Current FY 2026-12-31 |
$-3.48 | $-4.88 | $-2.63 | -5.9% | +0.3% | 1↑ 2↓ | $0.1B | -65.6% | 7 |
| Next FY 2027-12-31 |
$-3.10 | $-4.55 | $-1.55 | 10.9% | +2.0% | 1↑ 2↓ | $0.1B | 9.4% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.814 | |
| 7d ago | $-0.810 | -0.004 |
| 30d ago | $-0.775 | -0.039 |
| 60d ago | $-0.813 | -0.001 |
| 90d ago | $-0.885 | +0.071 |
8 analyst firms have rated this stock: 1 upgrades, 2 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 4, 2026 | LifeSci Capital | INITIATE | — | Outperform |
| May 11, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| May 7, 2026 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Apr 2, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 5, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 2, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Mar 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 12, 2026 | Wells Fargo | DOWNGRADE | Overweight | Equal-Weight |
| Jan 13, 2026 | Goldman Sachs | UPGRADE | Neutral | Buy |
| Jan 8, 2026 | Morgan Stanley | DOWNGRADE | Overweight | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 9 | 4 | 0 | 0 | 78% | |
| May 1, 2026 | 5 | 9 | 4 | 0 | 0 | 78% | |
| Apr 1, 2026 | 5 | 9 | 4 | 0 | 0 | 78% | |
| Mar 1, 2026 | 5 | 9 | 4 | 0 | 0 | 78% | |
| Feb 1, 2026 | 5 | 10 | 3 | 0 | 0 | 83% | |
| Jan 1, 2026 | 5 | 10 | 3 | 0 | 0 | 83% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 12, 2026
short_volume
Short Volume: RCUS — 63.2% short (0.3M / 0.5M)
Short: 344,544 | Exempt: 124 | TRF Vol: 544,987 | Short Ratio: 63.2% | Off-exchange volume (dark pool + OTC)
Jun 11, 2026
Clinical Trial
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
Phase Phase 2 — COMPLETED
Jun 11, 2026
short_volume
Short Volume: RCUS — 74.6% short (0.4M / 0.6M)
Short: 441,494 | Exempt: 900 | TRF Vol: 591,898 | Short Ratio: 74.6% | Off-exchange volume (dark pool + OTC)
Jun 10, 2026
short_volume
Short Volume: RCUS — 90.5% short (1.1M / 1.3M)
Short: 1,139,631 | Exempt: 100 | TRF Vol: 1,258,816 | Short Ratio: 90.5% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
short_volume
Short Volume: RCUS — 87.8% short (0.5M / 0.6M)
Short: 543,666 | Exempt: 0 | TRF Vol: 619,157 | Short Ratio: 87.8% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: RCUS — 60.7% short (0.4M / 0.7M)
Short: 411,700 | Exempt: 3,387 | TRF Vol: 678,751 | Short Ratio: 60.7% | Off-exchange volume (dark pool + OTC)
May 6, 2026
short_volume
Short Volume: RCUS — 72.1% short (0.5M / 0.7M)
Short: 530,335 | Exempt: 49,220 | TRF Vol: 735,538 | Short Ratio: 72.1% | Off-exchange volume (dark pool + OTC)
May 5, 2026
earnings_calendar
RCUS Q1 2026 Earnings After Market Close — 2026-05-05
Apr 22, 2026
short_volume
Short Volume: RCUS — 60.4% short (1.5M / 2.5M)
Short: 1,540,593 | Exempt: 65,756 | TRF Vol: 2,549,263 | Short Ratio: 60.4% | Off-exchange volume (dark pool + OTC)
Apr 20, 2026
short_volume
Short Volume: RCUS — 64.0% short (0.4M / 0.6M)
Short: 405,588 | Exempt: 1,535 | TRF Vol: 633,314 | Short Ratio: 64.0% | Off-exchange volume (dark pool + OTC)
Apr 2, 2026
short_volume
Short Volume: RCUS — 84.1% short (0.5M / 0.6M)
Short: 544,091 | Exempt: 5,795 | TRF Vol: 646,651 | Short Ratio: 84.1% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
Clinical Trial
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Apr 1, 2026
clinical_trial_readout
T-90d Trial Readout: Domvanalimab (Phase 3)
Trial: A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tr
Apr 1, 2026
short_volume
Short Volume: RCUS — 67.4% short (0.4M / 0.6M)
Short: 379,915 | Exempt: 624 | TRF Vol: 563,712 | Short Ratio: 67.4% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
clinical_trial_readout
T-90d Trial Readout: Domvanalimab (Phase 3)
Trial: A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tr
Mar 30, 2026
clinical_trial_readout
T-90d Trial Readout: Domvanalimab (Phase 3)
Trial: A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tr
Mar 3, 2026
short_interest
FTD: RCUS — 30,000 shares ($0.7M) failed to deliver
Settlement: 20260303, Price: $23.94, FTD Value: $718,200, ARCUS BIOSCIENCES INC